학술논문
A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis
Document Type
Article
Author
Bowlus, C.L.; Galambos, M.R.; Aspinall, R.J.; Hirschfield, G.M.; Jones, D.E.J.; Dörffel, Y.; Gordon, S.C.; Harrison, S.A.; Kremer, A.E.; Mayo, M.J.; Thuluvath, P.J.; Levy, C.; Swain, M.G.; Neff, G.W.; Sheridan, D.A.; Stanca, C.M.; Berg, C.P.; Goel, A.; Shiffman, M.L.; Vierling, J.M.; Boudes, P.; Steinberg, A.; Choi, Y.-J.; McWherter, C.A.
Source
In: Journal of Hepatology . (Journal of Hepatology, August 2022, 77(2):353-364)
Subject
Language
English
ISSN
16000641
01688278
01688278